Search / Trial NCT06234319

CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma

Launched by XIAO CHEN · Jan 29, 2024

Trial Information

Current as of October 07, 2024

Recruiting

Keywords

Description

1. PET/MRI Scan: Image acquisition was completed 15 days before surgery. CXCR4 contrast agent was injected at 6.5 MBq/kg based on body mass, with no drug extravasation, and imaging was performed after 60 minutes of quiet rest. All subjects were scanned in a supine position on a single bed of the Signa™ 3.0T scanner (GE Healthcare Systems), using a 3.0T gem HNU head coil with a scanning field of view focused on the head. PET acquisition lasted for 20 minutes and was reconstructed using OSEM. Simultaneous MRI acquisition included MR-based attenuation correction (MRAC) - zero echo time pulse s...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients diagnosed with primary glioma based on clinical, imaging, and histopathological criteria;
  • 2. The patient is at least 18 years old;
  • 3. Participate in CXCR4 PET/MRI imaging within 15 days before surgery;
  • 4. Surgical resection of glioma lesion tissue can be used for pathological analysis;
  • 5. The patient voluntarily participates and signs the informed consent form.
  • Exclusion Criteria:
  • 1. Pregnant or breastfeeding patients;
  • 2. The image quality of the imaging is poor and cannot be used for diagnosis and evaluation;
  • 3. Molecular typing was not determined by histologic examination;
  • 4. patients with claustrophobia;
  • 5. Patients who are allergic to radioactive tracers and MRI contrast agents, and patients with renal insufficiency.

About Xiao Chen

Xiao Chen is a dedicated clinical trial sponsor focused on advancing medical research and innovation through rigorous and ethical clinical studies. With a commitment to improving patient outcomes, Xiao Chen collaborates with healthcare professionals, research institutions, and regulatory bodies to design and implement trials that adhere to the highest standards of scientific integrity and compliance. By leveraging cutting-edge methodologies and a patient-centered approach, Xiao Chen aims to contribute valuable insights to the medical community, ultimately enhancing the development of effective treatments and therapies.

Locations

Chongqing, Chongqing, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0